DRUG

Bright Minds Biosciences Inc.

Price Chart

Latest Quote

$60.66

+1.14 (+1.92%)

Current Price

Previous Close	$59.52
Open	$61.22
Day High	$62.25
Day Low	$59.00
Volume	238,643

Fetched: 2026-06-20T22:34:56

Stock Information

Note: Financial values converted from CAD to USD

Shares Outstanding	9.81M
Total Debt	$58K
Cash Equivalents	$218.88M
Net Income	$-19.33M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$595.20M
EPS (TTM)	$-2.44
Exchange	NCM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$285.59M
Income	$-19.33M
Book/sh	$22.47
Cash/sh	$31.56
Employees	26

Financial Ratios

Quick Ratio	81.10
Current Ratio	81.48
Debt/Eq	0.03

Returns & Margins

ROA	-10.44%
ROE	-15.02%

Ownership

Insider Ownership	12.02%
Institutional Ownership	92.82%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-7.11
P/B	2.70

Analyst Data

Recommendation	none
Target Price	$165.56

Technical Indicators

SMA20	$72.48
SMA50	$80.54
SMA200	$72.82
RSI	12.15
ATR	5.2959

Shares Float	5.13M
Short Float	10.66%
Short Ratio	3.45
Volatility	-0.11
Rel Volume	0.53

Performance History

Week	-1.48%
Month	-18.62%
Quarter	-16.08%
6 Months	-35.46%
YTD	-27.32%
Year	+119.07%
3 Years	+2066.43%
5 Years	+171.41%
10 Years	+124.67%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-18	$60.66	239,400
2026-06-17	$59.52	152,600
2026-06-16	$59.82	223,500
2026-06-15	$59.17	938,900
2026-06-12	$60.95	658,900
2026-06-11	$61.57	582,700
2026-06-10	$61.56	708,300
2026-06-09	$67.80	365,500
2026-06-08	$65.28	352,600
2026-06-05	$69.00	712,300
2026-06-04	$74.50	825,000
2026-06-03	$74.42	761,500
2026-06-02	$76.78	509,100
2026-06-01	$81.02	327,400
2026-05-29	$88.07	219,600
2026-05-28	$89.49	264,500
2026-05-27	$87.04	253,100
2026-05-26	$86.28	199,100
2026-05-22	$83.50	281,100
2026-05-21	$83.24	517,800
2026-05-20	$82.78	201,400
2026-05-19	$74.54	235,600

About Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.

📰 Latest News

Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline

Motley Fool • 2026-05-21T21:51:11Z

What Is the Probability of Success for Bright Minds Biosciences Inc (DRUG)’s Lead Drug Candidate?

Insider Monkey • 2026-03-25T05:34:11Z

Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results

TipRanks • 2026-03-06T15:15:45Z

Baird Lowers Bright Minds Biosciences Inc. (DRUG) Price Target to $126, Maintains Outperform Rating Ahead of Upcoming Trials

Insider Monkey • 2026-02-19T02:31:00Z

Recent Price Trend in Bright Minds Biosciences Inc. (DRUG) is Your Friend, Here's Why

Zacks • 2025-11-26T13:55:03Z

Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 36.27%: Read This Before Placing a Bet

Zacks • 2025-11-25T14:55:03Z

Bright Minds Biosciences Inc. (DRUG) is on the Move, Here's Why the Trend Could be Sustainable

Zacks • 2025-10-15T12:50:03Z

Wall Street Analysts Believe Bright Minds Biosciences Inc. (DRUG) Could Rally 81.29%: Here's is How to Trade

Zacks • 2025-09-18T13:55:01Z

Large Patient Population Is Key Driver For Bright Minds' Growth

Benzinga • 2025-09-08T17:54:11Z

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Market Exclusive • 2025-09-07T21:29:39Z

Period:

Income Statement (Annual)

Metric	2025-09-30	2024-09-30	2023-09-30	2022-09-30
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Total Expenses	$9,848,491	$1,994,606	$5,219,343	$10,581,608
Other Income Expense	$133,386	$-6,580	$10,026	$7,173
Net Non Operating Interest Income Expense	$1,073,677	$21,292	$0	$0
Operating Expense	$9,848,491	$1,994,606	$5,219,343	$10,581,608
Other Operating Expenses	$203,255	$139,334	$131,890	$171,763
Selling And Marketing Expense	$303,603	$29,395	$84,382	$389,955
General And Administrative Expense	$1,509,165	$992,065	$1,470,040	$1,412,670
Other Non Operating Income Expenses	-	-	-	$-171,763
Total Other Finance Cost	-	-	-	-
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-8,641,427	$-1,979,894	$-5,209,317	$-10,574,435
Net Interest Income	$1,073,677	$21,292	$0	$0
Interest Income	$1,073,677	$21,292	$0	$0
Normalized Income	$-8,774,813	$-1,973,314	$-5,219,343	$-10,581,608
Net Income From Continuing And Discontinued Operation	$-8,641,427	$-1,979,894	$-5,209,317	$-10,574,435
Net Income Common Stockholders	$-8,641,427	$-1,979,894	$-5,209,317	$-10,574,435
Net Income	$-8,641,427	$-1,979,894	$-5,209,317	$-10,574,435
Net Income Including Noncontrolling Interests	$-8,641,427	$-1,979,894	$-5,209,317	$-10,574,435
Net Income Continuous Operations	$-8,641,427	$-1,979,894	$-5,209,317	$-10,574,435
Pretax Income	$-8,641,427	$-1,979,894	$-5,209,317	$-10,574,435
Interest Income Non Operating	$1,073,677	$21,292	$0	$0
Operating Income	$-9,848,491	$-1,994,606	$-5,219,343	$-10,581,608
Special Income Charges	-	$0	$0	$-1,413
Per Share
Diluted EPS	$-1.26	$-0.46	$-1.40	$-4.28
Basic EPS	$-1.26	$-0.46	$-1.40	$-4.28
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-9,927,561	$-1,936,191	$-5,178,175	$-10,584,515
Total Unusual Items	$133,386	$-6,580	$10,026	$7,173
Total Unusual Items Excluding Goodwill	$133,386	$-6,580	$10,026	$7,173
Reconciled Depreciation	$54,316	$51,835	$51,194	$4,266
EBITDA (Bullshit earnings)	$-9,794,175	$-1,942,771	$-5,168,149	$-10,577,342
EBIT	$-9,848,491	$-1,994,606	$-5,219,343	$-10,581,608
Diluted Average Shares	$4,860,126	$3,045,625	$2,628,445	$1,745,607
Basic Average Shares	$4,860,126	$3,045,625	$2,628,445	$1,745,607
Diluted NI Availto Com Stockholders	$-8,641,427	$-1,979,894	$-5,209,317	$-10,574,435
Gain On Sale Of Security	$133,386	$-6,580	$10,026	$8,586
Research And Development	$7,832,468	$833,811	$3,533,030	$8,607,220
Selling General And Administration	$1,812,768	$1,021,461	$1,554,423	$1,802,625
Other Gand A	$1,157,761	$643,144	$652,825	$1,342,406
Salaries And Wages	$351,403	$348,921	$817,215	$70,264
Impairment Of Capital Assets	-	$0	$0	$1,413

Fetched: 2026-06-20

Balance Sheet (Annual)

Metric	2025-09-30	2024-09-30	2023-09-30	2022-09-30
Assets
Net Tangible Assets	$57,974,083	$3,912,057	$4,662,391	$7,449,486
Total Assets	$59,653,433	$4,313,597	$4,860,848	$8,540,831
Total Non Current Assets	$79,118	$83,139	$46,928	$98,123
Current Assets	$59,574,315	$4,230,458	$4,813,920	$8,442,708
Prepaid Assets	$698,072	$153,072	$19,568	$116,188
Receivables	$291,882	$35,489	$26,131	$110,076
Taxes Receivable	$148,331	$35,489	$26,131	$80,920
Accrued Interest Receivable	$143,551	$0	-	-
Cash Cash Equivalents And Short Term Investments	$58,584,361	$4,041,897	$4,768,221	$8,216,445
Cash And Cash Equivalents	$58,584,361	$4,041,897	$4,768,221	$8,216,445
Cash Equivalents	$60,945	$60,945	$60,945	$60,945
Cash Financial	$58,523,416	$3,980,951	$4,707,275	$8,155,500
Goodwill And Other Intangible Assets	-	-	-	$0
Other Receivables	-	-	-	$29,156
Debt
Total Debt	$88,876	$84,059	$51,971	$98,863
Long Term Debt And Capital Lease Obligation	$29,147	$27,965	$0	$50,864
Current Debt And Capital Lease Obligation	$59,729	$56,094	$51,971	$47,999
Liabilities
Total Liabilities Net Minority Interest	$1,679,350	$401,540	$198,457	$1,091,345
Total Non Current Liabilities Net Minority Interest	$29,147	$27,965	$0	$50,864
Current Liabilities	$1,650,203	$373,575	$198,457	$1,040,481
Payables And Accrued Expenses	$1,590,474	$317,481	$146,486	$992,482
Payables	$1,208,515	$287,979	$128,821	$880,712
Accounts Payable	$1,208,515	$287,979	$128,821	$880,712
Equity
Common Stock Equity	$57,974,083	$3,912,057	$4,662,391	$7,449,486
Total Equity Gross Minority Interest	$57,974,083	$3,912,057	$4,662,391	$7,449,486
Stockholders Equity	$57,974,083	$3,912,057	$4,662,391	$7,449,486
Gains Losses Not Affecting Retained Earnings	$3,796,921	$2,830,955	$2,401,849	$1,752,025
Retained Earnings	$-32,912,886	$-24,271,459	$-22,291,565	$-17,082,248
Other Equity Interest	-	$321,914	$587,785	-
Other
Ordinary Shares Number	$5,395,555	$3,196,783	$2,665,399	$2,486,201
Share Issued	$5,395,555	$3,196,783	$2,665,399	$2,486,201
Tangible Book Value	$57,974,083	$3,912,057	$4,662,391	$7,449,486
Invested Capital	$57,974,083	$3,912,057	$4,662,391	$7,449,486
Working Capital	$57,924,112	$3,856,883	$4,615,463	$7,402,227
Capital Lease Obligations	$88,876	$84,059	$51,971	$98,863
Total Capitalization	$57,974,083	$3,912,057	$4,662,391	$7,449,486
Capital Stock	$87,090,049	$25,030,646	$23,964,321	$22,779,709
Common Stock	$87,090,049	$25,030,646	$23,964,321	$22,779,709
Long Term Capital Lease Obligation	$29,147	$27,965	$0	$50,864
Current Capital Lease Obligation	$59,729	$56,094	$51,971	$47,999
Current Accrued Expenses	$381,959	$29,502	$17,665	$111,770
Net PPE	$79,118	$83,139	$46,928	$98,123
Gross PPE	$79,118	$83,139	$46,928	$98,123
Leases	$79,118	$83,139	$46,928	$98,123
Properties	$0	$0	$0	$0
Other Properties	-	-	-	$98,123

Fetched: 2026-06-20

Cash Flow Statement (Annual)

Metric	2025-09-30	2024-09-30	2023-09-30	2022-09-30
Free Cash Flow
Free Cash Flow	$-6,141,619	$-1,307,367	$-4,963,443	$-9,600,845
Operating Activities
Operating Cash Flow	$-6,141,619	$-1,307,367	$-4,963,443	$-9,600,845
Cash Flow From Continuing Operating Activities	$-6,141,619	$-1,307,367	$-4,963,443	$-9,600,845
Operating Gains Losses	$-220,949	$-7,155	$32,044	$-182,889
Financing Activities
Issuance Of Capital Stock	$58,011,280	$635,953	$860,302	$2,851,105
Financing Cash Flow	$60,463,179	$572,761	$1,547,263	$3,671,700
Cash Flow From Continuing Financing Activities	$60,463,179	$572,761	$1,547,263	$3,671,700
Net Other Financing Charges	$-254,479	-	$-19,062	$-565,276
Net Common Stock Issuance	$58,011,280	$635,953	$860,302	$2,851,105
Common Stock Issuance	$58,011,280	$635,953	$860,302	$2,851,105
Other
Repayment Of Debt	$-70,767	$-63,404	$-60,848	$-5,061
End Cash Position	$58,584,361	$4,041,897	$4,768,221	$8,216,445
Beginning Cash Position	$4,041,897	$4,768,221	$8,216,445	$13,962,701
Effect Of Exchange Rate Changes	$220,905	$8,282	$-32,044	$182,889
Changes In Cash	$54,321,560	$-734,606	$-3,416,181	$-5,929,145
Proceeds From Stock Option Exercised	$2,777,145	$213	$766,870	$1,390,932
Net Issuance Payments Of Debt	$-70,767	$-63,404	$-60,848	$-5,061
Net Long Term Debt Issuance	$-70,767	$-63,404	$-60,848	$-5,061
Long Term Debt Payments	$-70,767	$-63,404	$-60,848	$-5,061
Change In Working Capital	$392,166	$28,132	$-665,432	$511,682
Change In Payables And Accrued Expense	$1,193,558	$170,995	$-845,996	$541,258
Change In Prepaid Assets	$-544,999	$-133,505	$96,620	$2,670
Change In Receivables	$-256,393	$-9,358	$83,944	$-32,245
Other Non Cash Items	$25,333	$6,321	$13,956	$20,791
Stock Based Compensation	$2,248,942	$593,394	$814,112	$618,327
Depreciation Amortization Depletion	$54,316	$51,835	$51,194	$4,266
Depreciation And Amortization	$54,316	$51,835	$51,194	$4,266
Depreciation	$54,316	$51,835	$51,194	$4,266
Net Foreign Currency Exchange Gain Loss	$-220,949	$-7,155	$32,044	$-182,889
Net Income From Continuing Operations	$-8,641,427	$-1,979,894	$-5,209,317	$-10,574,435
Asset Impairment Charge	-	$0	$0	$1,413
Change In Other Current Liabilities	-	-	-	$1,535

Fetched: 2026-06-20